Bowel Cancer Relapse: Cheap Medicine Halves Risk
- A new study published in The New England Journal of Medicine on September 17, 2025, suggests that low-dose aspirin may considerably improve outcomes for patients with localized colorectal...
- Anna Martling,a lead researcher on the study,emphasized the significant advantage of using aspirin due to its global availability and low cost.
- The study focused on patients whose localized colorectal cancer displayed alterations in the PI3K gene.The PI3K pathway is frequently dysregulated in cancer, promoting cell growth and survival.
“`html
Low-Dose Aspirin Shows Promise in Treating Localized Colorectal Cancer
Table of Contents
Published September 18, 2025
Key Findings
A new study published in The New England Journal of Medicine on September 17, 2025, suggests that low-dose aspirin may considerably improve outcomes for patients with localized colorectal cancer exhibiting alterations in the PI3K gene. Researchers analyzed data from over 3,500 patients across 33 hospitals and found a correlation between aspirin use and improved survival rates in this specific patient group. “Low-Dose Aspirin for PI3K-Altered Localized colorectal Cancer”, by Anna Martling et al.
Aspirin’s Accessibility: A Major Advantage
Anna Martling,a lead researcher on the study,emphasized the significant advantage of using aspirin due to its global availability and low cost. “aspirin is a drug that is easily accessible globally and extremely cheaply compared to many modern cancer drugs, wich is very positive,” Martling stated. This accessibility could have a substantial impact on cancer treatment worldwide, particularly in regions with limited resources.
The PI3K Connection
The study focused on patients whose localized colorectal cancer displayed alterations in the PI3K gene.The PI3K pathway is frequently dysregulated in cancer, promoting cell growth and survival. The research suggests that aspirin might potentially be particularly effective in counteracting the effects of these PI3K alterations.
Study Details and Funding
The research involved a retrospective analysis of data from 3,500+ patients diagnosed with colon or rectal cancer and treated at 33 hospitals. The study was funded by the Swedish Research Council and the Cancer Foundation. Researchers have declared no conflicts of interest.
Potential Impact on Treatment Guidelines
researchers believe the findings could lead to changes in international treatment guidelines for colon and rectal cancer. If confirmed by further studies,incorporating low-dose aspirin into treatment protocols could offer a cost-effective and accessible option for improving patient outcomes.